“Selecting the Optimal Treatment Line for CDK4 6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer”. Voprosy Onkologii, vol. 72, no. 3, July 2026, p. OF-2455, https://doi.org/10.37469/0507-3758-2026-72-3-OF-2455.